A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
← catalyst calendarNCT07024823 · readout in 128 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
124estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-09 | actual | When the study began enrolling |
| Primary completion | 2026-12-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-25 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Kidney Disease
Interventions
- Drug: AZD4248
- Drug: Placebo
- Drug: AZD4248
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFParts A, B, and C: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured From Day 1 to Follow Up visit (Part A: up to 12 days; Part B and C: up to 19 days)
Part D: Intra- and inter-participant variability of estimated glomerular filtration rate (eGFR) derived from home self-testing device measurements
measured Day 1 to Day 169
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed